Madrid, Spain – 30 August 2025: Baxdrostat 1 mg or 2 mg once daily led to statistically significant reductions in blood pressure compared with placebo at 12 weeks in patients with uncontrolled or treatment-resistant hypertension, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

 

 

The proportion of patients with controlled SBP (<130 mmHg) after 12 weeks was 39.4% with baxdrostat 1 mg, 40% with baxdrostat 2 mg and 18.7% with placebo.  

 

 

Professor Williams concluded: “These BaxHTN trial findings are an important advance in treatment and in our understanding of the cause of hard-to-control BP. In patients with uncontrolled or resistant hypertension, the addition of baxdrostat 1 mg or 2 mg once daily to background antihypertensive therapy led to clinically meaningful reductions in SBP, with no unanticipated safety findings. This suggests that aldosterone is playing an important role in causing hard-to-control BP and offers hope for more effective treatment in the future.” 

https://www.escardio.org/The-ESC/Press-Office/Press-releases/Blood-pressure-reductions-with-baxdrostat-in-patients-with-uncontrolled-or-resistant-hypertension

2 hours ago, Bacon1 said:

Madrid, Spain – 30 August 2025: Baxdrostat 1 mg or 2 mg once daily led to statistically significant reductions in blood pressure compared with placebo at 12 weeks in patients with uncontrolled or treatment-resistant hypertension, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

 

 

The proportion of patients with controlled SBP (<130 mmHg) after 12 weeks was 39.4% with baxdrostat 1 mg, 40% with baxdrostat 2 mg and 18.7% with placebo.  

 

 

Professor Williams concluded: “These BaxHTN trial findings are an important advance in treatment and in our understanding of the cause of hard-to-control BP. In patients with uncontrolled or resistant hypertension, the addition of baxdrostat 1 mg or 2 mg once daily to background antihypertensive therapy led to clinically meaningful reductions in SBP, with no unanticipated safety findings. This suggests that aldosterone is playing an important role in causing hard-to-control BP and offers hope for more effective treatment in the future.” 

https://www.escardio.org/The-ESC/Press-Office/Press-releases/Blood-pressure-reductions-with-baxdrostat-in-patients-with-uncontrolled-or-resistant-hypertension

It is indeed an advance in treatment vs Spironolactone, which shows side effects as Gynecomastia (men) and menstruation anomalies (women)